Galena Biopharma Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 17 Posts
1 2
Beware Of Fake Stock News In The Financial Markets
Article By: TipRanks Sunday, April 23, 2017 4:56 PM EDT
The US Securities and Exchange Commission (SEC) is taking legal action against 27 individuals and several companies over hundreds of fake “impartial” blog posts that appeared on well-known financial websites.
In this article: ONCS, GALE, PBYI, ARTH, LBIO
Read
Five Companies Whose Litigation Could Affect Their Bottom Line
Article By: Shazir Mucklai Thursday, March 30, 2017 6:52 PM EDT
Most lawsuits will not affect a company’s bottom line. However, here are five companies that stand to win/lose big this year based on current litigation.
In this article: JNJ, TSLA, GALE, WFC, VLKAF
Read
Most Active Stock Options For End Of Day March 2, 2017
Article By: The Options Insider Thursday, March 2, 2017 5:15 PM EDT
The most active stock options for end of day Thursday: BAC, RAI, AAPL, GALE and AMD.
In this article: BAC, RAI, AAPL, GALE, AMD
Read
Bet On Stocks With Rising P/E To Enjoy Growing Gains
Article By: Zacks Investment Research Monday, November 28, 2016 9:46 AM EDT
Betting on bargain stocks that have a low price-to-earnings (P/E) ratio is a convenient investment approach. The perception is that the lower the P/E, the higher is the value of the stock.
In this article: CBM, HUM, GALE, REFR, EPC
Read
Galena Biopharma Announces Pricing Of Registered Direct Offering
Article By: NASDAQ GlobeNewswire Friday, July 8, 2016 10:39 PM EDT
It has entered into agreements for the issuance of 28,000,000 shares at $0.45 in a registered direct offering, and warrants to purchase up to 14,000,000 shares with an exercise price of $0.65 in a concurrent private placement,
In this article: GALE
Read
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Article By: The Life Sciences Report Wednesday, March 9, 2016 5:47 PM EDT
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO
Read
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Article By: The Life Sciences Report Wednesday, January 27, 2016 6:16 PM EDT
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
E Galena Biopharma Announces Reduction Of Cardiac Toxicity Study For Neuvax Trial
Article By: Terry Chrisomalis Monday, August 24, 2015 6:39 PM EDT
Shares of Galena Biopharma (GALE) closed the day up 11%, after announcing reduction of cardiac toxicity study for Neuvax trial.
In this article: GALE
Read
E Galena Biopharma Launches Anti-Nausea Drug Zuplenz
Article By: Terry Chrisomalis Wednesday, July 29, 2015 2:31 PM EDT
Galena Biopharma shares are up 5% after announcing the launch of an anti-nausea drug known as Zuplenz, indicated for use in post-chemo, post-radiation and post-surgical patients.
In this article: GALE
Read
Gilead’s Hep C Drug Receives Approval In Japan - Analyst Reactions
Article By: TipRanks Tuesday, March 31, 2015 10:58 AM EDT
Sovaldi becomes the first Gilead drug available in Japan. Overall analyst consensus is Strong Buy.
In this article: GILD, MDVN, GALE
Read
Galena Biopharma Releases Q4 Report Amid SEC Investigation
Article By: TipRanks Sunday, March 8, 2015 10:57 AM EDT
Galena Biopharma (NASDAQ: GALE) reported fourth quarter and year-end 2014 results on March 5th. The biopharmaceutical company specializes in oncology drugs and saw significant advancements in NeuVax, a drug used to prevent recurring cancers in survivors.
In this article: GALE
Read
Provectus Biopharmaceuticals Concludes FDA Meeting For PV-10 Phase 3; Successful Completion Of AB Science's Futility Test For Masitinib
Article By: BioMedReports Tuesday, February 10, 2015 5:59 AM EDT
Here is a look at some of the headlines for companies that made news in the healthcare sector on February 9, 2015.
In this article: ACHN, AKBS, AKR.L, AVXL, BIOC, BMRN, BSDM, CLDX, CBMG, CEMI, ENSG, GALE, ICUI, ISLT, IART, JUNO, LJPC, LFVN, MJNA, HTGC, NSPH, OREX, RDHL.TA, RCPT, RGLS, RNN, SBRA, WMGI, VBLT
Read
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Article By: BioMedReports Friday, January 16, 2015 3:44 AM EDT
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI
Read
Biotech Stocks: The Sector's Most Comprehensive Immunotherapy Platforms
Article By: BioMedReports Friday, November 7, 2014 4:58 AM EDT
The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
In this article: INO, NWBO, TPIV, DNDN, GALE
Read
Active Stocks: PSivida, Galena Biopharma, Cytokinetics, Epizyme, Alexza Pharmaceuticals
Article By: BioMedReports Monday, October 27, 2014 6:22 PM EDT
Stocks wavered around the unchanged mark in afternoon trade Monday, as investors paused following the biggest weekly gains for major indexes in more than a year.
In this article: ALXA, CYTK, PSDV, GALE, EPZM
Read
EC Bioniche: A Home Run Buying Opportunity In Biotech
Article By: SecretCaps Thursday, September 18, 2014 9:38 AM EDT
There is a critical medical need for Bioniche's technology in a $1 billion market virtually free of real competition, which opens the door for massive revenue growth, while the sound financials limits downside risk. Overall, today's $0.20 share price appears to me as an excellent entry point...
In this article: BNHLF, ECYT, ONTY, GALE
Read
1 to 16 of 17 Posts
1 2